Advanced imaging applied to radiotherapy planning in head and neck cancer: A clinical review

British Journal of Radiology

Volumn 79, Issue 943, 2006, Pages 554-561

  Newbold, K ^a   Partridge, M ^a   Cook, G ^a   Sohaib, S A ^a   Charles Edwards, E ^a   Rhys Evans, P ^a   Harrington, K ^a   Nutting, C ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBON 11; CHOLINE; CONTRAST MEDIUM; COPPER 62; DEOXYURIDINE; FLUORODEOXYGLUCOSE F 18; IODINE 124; METHIONINE; MISONIDAZOLE; RADIOPHARMACEUTICAL AGENT; THYMIDINE;

CANCER LOCALIZATION; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DOSIMETRY; HEAD AND NECK CANCER; HUMAN; HYPOXIA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGICAL ANATOMY; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; VALIDATION PROCESS;

ANOXIA; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33746132473     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/48822193     Document Type: Review

References (56)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Yousem DM, Som PM, Hackney DB, Schwaibold F, Hendrix RA. Central nodal necrosis and extracapsular neoplastic spread in cervical lymph nodes: MR imaging versus CT. Radiology 1992;182:753-9.
3. Curtin HD, Ishwaran H, Mancuso AA, Dalley RW, Caudry DJ, McNeil BJ. Comparison of CT and MR imaging in staging of neck metastases. Radiology 1998;207:123-30.
4. Hermans R, Feron M, Bellon E, Dupont P, Van den Bogaert W, Baert AL. Laryngeal tumor volume measurements determined with CT: a study on intra- and interobserver variability. Int J Radiat Oncol Biol Phys 1998;40:553-7.
5. Guerrero Urbano MT, Nutting CM. Clinical use of intensity-modulated radiotherapy: part I. Br J Radiol 2004;77:88-96.
6. Guerrero Urbano MT, Nutting CM. Clinical use of intensity-modulated radiotherapy: part II. Br J Radiol 2004;77:177-82.
7. Khoo VS, Dearnaley DP, Finnigan DJ, Padhani A, Tanner SF, Leach MO. Magnetic resonance imaging (MRI): considerations and applications in radiotherapy treatment planning. Radiother Oncol 1997;42:1-15.
8. Leslie A, Fyfe E, Guest P, Goddard P, Kabala JE. Staging of squamous cell carcinoma of the oral cavity and oropharynx: a comparison of MRI and CT in T- and N-staging. J Comput Assist Tomogr 1999;23:43-9.
9. Chung NN, Ting LL, Hsu WC, Lui LT, Wang PM. Impact of magnetic resonance imaging versus CT on nasopharyngeal carcinoma: primary tumor target delineation for radiotherapy. Head Neck 2004;26:241-6.
10. Emami B, Sethi A, Petruzzelli GJ. Influence of MRI on target volume delineation and IMRT planning in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2003;57:481-8.
11. Aoyama H, Shirato H, Nishioka T, Hashimoto S, Tsuchiya K, Kagei K, et al. Magnetic resonance imaging system for three-dimensional conformal radiotherapy and its impact on gross tumor volume delineation of central nervous system tumors. Int J Radiat Oncol Biol Phys 2001;50:821-7.
12. Tanner SF, Finnigan DJ, Khoo VS, Mayles P, Dearnaley DP, Leach MO. Radiotherapy planning of the pelvis using distortion corrected MR images: The removal of system distortion. Phys Med Biol 2000;45:2117-32.
13. Doran SJ, Charles-Edwards L, Reinsberg S, Leach MO. A complete distortion correction for MR images: I Gradient warp correction. Phys Med Biol (In press).
14. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551-60.
15. Schoder H, Yeung HW, Gonen M, Kraus D, Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004;231:65-72.
16. Schmid DT, Stoeckli SJ, Bandhauer F, Huguenin P, Schmid S, von Schulthess GK, et al. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope 2003;113:888-91.
17. Dizendorf EV, Baumert BG, von Schulthess GK, Lutolf UM, Steinert HC. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 2003;44:24-9.
18. Kresnik E, Mikosch P, Gallowitsch HJ, Kogler D, Wiesser S, Heinisch M, et al. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods. Eur J Nucl Med 2001;28:816-21.
19. Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999;109:880-5.
20. Kau RJ, Alexiou C, Laubenbacher C, Werner M, Schwaiger M, Arnold W. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Arch Otolaryngol Head Neck Surg 1999;125:1322-8.
21. Nowak B, Di Martino E, Janicke S, Cremerius U, Adam G, Zimny M, et al. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin 1999;38:312-8.
22. Wong WL, Saunders M. The impact of FDG PET on the management of occult primary head and neck tumours. Clin Oncol (R Coll Radiol) 2003;15:461-6.
23. Fogarty GB, Peters LJ, Stewart J, Scott C, Rischin D, Hicks RJ. The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor. Head Neck 2003;25:138-45.
24. Paulino AC, Thorstad WL, Fox T. Role of fusion in radiotherapy treatment planning. Semin Nucl Med 2003;33:238-43.
25. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003;57:853-63.
26. Nishioka T, Shiga T, Shirato H, Tsukamoto E, Tsuchiya K, Kato T, et al. Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 2002;53:1051-7.
27. Scarfone C, Lavely WC, Cmelak AJ, Delbeke D, Martin WH, Billheimer D, et al. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. J Nucl Med 2004;45:543-52.
28. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34:274-92.
29. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:1171-82.
30. Pirzkall A, McKnight TR, Graves EE, Carol MP, Sneed PK, Wara WW, et al. MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys 2001;50:915-28.
31. Pouliot J, Kim Y, Lessard E, Hsu IC, Vigneron DB, Kurhanewicz J. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2004;59:1196-207.
32. Padhani AR, Husband JE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 2001;56: 607-20.
33. Padhani AR. MRI for assessing antivascular cancer treatments. Br J Radiol 2003;76 Spec. No. 1:S60-80.
34. Cooper RA, Carrington BM, Loncaster JA, Todd SM, Davidson SE, Logue JP, et al. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 2000;57:53-9.
35. Hoskin PJ, Saunders MI, Goodchild K, Powell ME, Taylor NJ, Baddeley H. Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol 1999;72:1093-8.
36. Axel L. Cerebral blood flow determination by rapid-sequence computed tomography: theoretical analysis. Radiology 1980;137:679-86.
37. Tateishi U, Nishihara H, Watanabe S, Morikawa T, Abe K, Miyasaka K. Tumor angiogenesis and dynamic CT in lung adenocarcinoma: radiologic-pathologic correlation. J Comput Assist Tomogr 2001;25:23-7.
38. Jinzaki M, Tanimoto A, Mukai M, Ikeda E, Kobayashi S, Yuasa Y, et al. Double-phase helical CT of small renal parenchymal neoplasms: correlation with pathologic findings and tumor angiogenesis. J Comput Assist Tomogr 2000;24:835-42.
39. Hermans R, Meijerink M, Van den Bogaert W, Rijnders A, Weltens C, Lambin P. Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:1351-6.
40. Dachs GU, Chaplin DJ. Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis. Semin Radiat Oncol 1998;8:208-16.
41. Horsman MR, Overgaard J. Overcoming tumour radiation resistance resulting from acute hypoxia. Eur J Cancer 1992;28A:2084-5.
42. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135-46.
43. Steel. G. Basic clinical radiobiology, 3rd edn. London: Hodder Arnold, 2002.
44. Popple RA, Ove R, Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys 2002;54:921-7.
45. Nutting CM, Corbishley CM, Sanchez-Nieto B, Cosgrove VP, Webb S, Dearnaley DP. Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escala tion of pathologically identified tumour nodules using intensity modulated radiotherapy. Br J Radiol 2002;75: 151-61.
46. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F] fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-28.
47. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155-60.
48. Taylor NJ, Baddeley H, Goodchild KA, Powell ME, Thoumine M, Culver LA, et al. BOLD MRI of human tumor oxygenation during carbogen breathing. J Magn Reson Imaging 2001;14:156-63.
49. Becker A, Hansgen G, Bloching M, Weigel C, Lautenschlager C, Dunst J. Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys 1998;42:35-41.
50. Rudat V, Vanselow B, Wollensack P, Bettscheider C, Osman-Ahmet S, Eble MJ, et al. Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer. Radiother Oncol 2000;57:31-7.
51. Whitmore GF, Varghese AJ, Gulyas S. Reaction of 2-nitroimidazole metabolites with guanine and possible biological consequences. IARC Sci Publ 1986:185-96.
52. Azuma C, Raleigh JA, Thrall DE. Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime. Radiat Res 1997;148:35-42.
53. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066-74.
54. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, et al. Expression of hypoxia-inducible factorlalpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61:2911-6.
55. Lal A, Peters H, St Croix B, Haroon ZA, Dewhirst MW, Strausberg RL, et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 2001;93:1337-43.
56. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001;61:6394-9.